Glaukos Corp Dossier
Qualitative Analysis
Business overview
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless therapies and associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) to advance the traditional glaucoma treatment paradigm. Its commercial portfolio includes the iStent family of micro-bypass devices, the iDose TR long-duration intracameral procedural pharmaceutical implant, and bio-activated pharmaceutical therapies for corneal cross-linking to treat keratoconus.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercial launch and market adoption of iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye.
Expected impact: Resets the conventional 'drops first' glaucoma care paradigm and serves as a primary driver of U.S. Glaucoma revenue growth.
Construction of a new 200,000 square foot research, development, and manufacturing facility in Huntsville, Alabama.
Expected impact: Designed to enhance operational capacity, support long-term innovation, and facilitate global growth.
Preparations for the 2026 commercial launch of Epioxa (Epi-on), the first and only FDA-approved topical drug therapy for keratoconus that does not require removal of the corneal epithelium.
Expected impact: Introduces the first incision-free treatment for keratoconus, expanding patient access and driving Corneal Health segment growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to secure and solidify the supply chain for Mitosol, the only FDA-approved ophthalmic formulation of mitomycin-C, which is utilized as an adjunct in late-stage glaucoma filtration procedures and alongside the PRESERFLO MicroShunt in active clinical trials.
Financial impact: The transaction was valued at $12.4 million net of cash acquired, with additional contingent single-digit royalty payments based on net sales for four years and performance-based payments of up to $80 million.